trending Market Intelligence /marketintelligence/en/news-insights/trending/3ueglhlehsy8kt01kvslaa2 content esgSubNav
In This List

Health Care Service Corp. curbs reimbursement of certain MiMedx treatments

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Health Care Service Corp. curbs reimbursement of certain MiMedx treatments

Health Care Service Corp. will cease reimbursing for injections of amniotic-tissue products made by MiMedx Group Inc. and other manufacturers, The Wall Street Journal reported.

The insurer said the products, touted as helping with hair loss, erectile dysfunction, knee pain and osteoarthritis, are "experimental, investigational and/or unproven for all indications." The insurer would only cover limited uses for amniotic skin grafts treatments, such as MiMedx's EpiFix allograft, according to the report.

The move took effect Aug. 1.